|
1
|
Lim SC and Hong R: Programmed cell death 4
(Pdcd4) expression in colorectal adenocarcinoma: Association with
clinical stage. Oncol Lett. 2:1053–1057. 2011.PubMed/NCBI
|
|
2
|
Alwan A: World Health Organization.
Disaster Med Public Health Prep. 1:7–8. 2007. View Article : Google Scholar
|
|
3
|
Ikenberg K, Fritzsche FR, Zuerrer-Haerdi
U, et al: Insulin-like growth factor II mRNA binding protein 3
(IMP3) is overexpressed in prostate cancer and correlates with
higher Gleason scores. BMC Cancer. 10:3412010. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Mentrikoski MJ, Ma L, Pryor JG, et al:
Diagnostic utility of IMP3 in segregating metastatic melanoma from
benign nevi in lymph nodes. Mod Pathol. 22:1582–1587. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Hoffmann NE, Sheinin Y, Lohse CM, et al:
External validation of IMP3 expression as an independent prognostic
marker for metastatic progression and death for patients with clear
cell renal cell carcinoma. Cancer. 112:1471–1479. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Jiang Z, Chu PG, Woda BA, et al:
Combination of quantitative IMP3 and tumor stage: a new system to
predict metastasis for patients with localized renal cell
carcinomas. Clin Cancer Res. 14:5579–5584. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Schaeffer DF, Owen DR, Lim HJ, et al:
Insulin-like growth factor 2 mRNA binding protein 3 (IGF2BP3)
overexpression in pancreatic ductal adenocarcinoma correlates with
poor survival. BMC Cancer. 10:592010. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Mhawech-Fauceglia P, Herrmann FR, Rai H,
et al: IMP3 distinguishes uterine serous carcinoma from endometrial
endometrioid adenocarcinoma. Am J Clin Pathol. 133:899–908. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Lu D, Yang X, Jiang NY, et al: IMP3, a new
biomarker to predict progression of cervical intraepithelial
neoplasia into invasive cancer. Am J Surg Pathol. 35:1638–1645.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Hammer NA, Hansen Tv, Byskov AG, et al:
Expression of IGF-II mRNA-binding proteins (IMPs) in gonads and
testicular cancer. Reproduction. 130:203–212. 2005. View Article : Google Scholar
|
|
11
|
Li C, Rock KL, Woda BA, et al: IMP3 is a
novel biomarker for adenocarcinoma in situ of the uterine cervix:
an immunohistochemical study in comparison with p16(INK4a)
expression. Mod Pathol. 20:242–247. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Gress TM, Müller-Pillasch F, Geng M, et
al: A pancreatic cancer-specific expression profile. Oncogene.
13:1819–1830. 1996.PubMed/NCBI
|
|
13
|
Nielsen J, Christiansen J, Lykke-Andersen
J, et al: A family of insulin-like growth factor II mRNA-binding
proteins represses translation in late development. Mol Cell Biol.
19:1262–1270. 1999.PubMed/NCBI
|
|
14
|
Tosun Yildirim H and Sentürk N: Analysis
of IMP3 expression in prostate adenocarcinomas. Turk Patoloji Derg.
28:128–133. 2012.PubMed/NCBI
|
|
15
|
Liao B, Hu Y, Herrick DJ and Brewer G: The
RNA-binding protein IMP-3 is a translational activator of
insulin-like growth factor II leader-3 mRNA during proliferation of
human K562 leukemia cells. J Biol Chem. 280:18517–18524. 2005.
View Article : Google Scholar
|
|
16
|
Jeng YM, Wang TH, Lu SH, et al: Prognostic
significance of insulin-like growth factor II mRNA-binding protein
3 expression in gastric adenocarcinoma. Br J Surg. 96:66–73. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Xu C, Jiang XZ, Zhao HF, et al: The
applicability of Ki-67 marker for renal epithelioid angiomyolipoma:
experience of ten cases from a single center. Neoplasma.
60:209–214. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Wang L, Li HG, Xia ZS, et al: IMP3 is a
novel biomarker to predict metastasis and prognosis of gastric
adenocarcinoma: a retrospective study. Chin Med J (Engl).
123:3554–3558. 2010.PubMed/NCBI
|
|
19
|
Sitnikova L, Mendese G, Liu Q, et al: IMP3
predicts aggressive superficial urothelial carcinoma of the
bladder. Clin Cancer Res. 14:1701–1706. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Yaniv K, Fainsod A, Kalcheim C and
Yisraeli JK: The RNA-binding protein Vg1 RBP is required for cell
migration during early neural development. Development.
130:5649–5661. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Yantiss RK, Cosar E and Fischer AH: Use of
IMP3 in identification of carcinoma in fine needle aspiration
biopsies of pancreas. Acta Cytol. 52:133–138. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Okada K, Fujiwara Y, Nakamura Y, et al:
Oncofetal protein, IMP-3, a potential marker for prediction of
postoperative peritoneal dissemination in gastric adenocarcinoma. J
Surg Oncol. 105:780–785. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Wachter DL, Kristiansen G, Soll C, et al:
Insulin-like growth factor II mRNA-binding protein 3 (IMP3)
expression in hepatocellular carcinoma. A clinicopathological
analysis with emphasis on diagnostic value. Histopathology.
60:278–286. 2012. View Article : Google Scholar
|
